Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Mar 24, 2016 | clinicaltrials |
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 0 | Aug 19, 2015 | clinicaltrials |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | withdrawn | Phase 2 | 0 | Cleveland BioLabsINDUSTRY | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | Apr 29, 2014 | clinicaltrials |
| NCT01639521 | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Jan 29, 2014 | clinicaltrials |
| NCT00025519 | Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Jul 11, 2013 | clinicaltrials |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00293527 | Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | May 23, 2013 | clinicaltrials |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | Andrea HarzstarkOTHER | 0 | Apr 8, 2013 | clinicaltrials |
| NCT00311545 | S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Feb 20, 2013 | clinicaltrials |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 17, 2013 | clinicaltrials |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | Jul 31, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 18, 2016source: clinicaltrials